Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...
4hon MSN
A Springfield resident and local real estate entrepreneur, Evan Plotkin has just been awarded $15 million after a jury found ...
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
The innovative medicine and medtech segments showed solid sales growth. Johnson & Johnson reported a strong increase in sales, but earnings fell due to one-time charges. In the wake of last year's ...
Naturally, much of the near 10-minute discussion was focused on the defense and its struggles. Just one year after leading ...
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Dwayne Johnson has previewed his "wild" festive blockbuster Red One ahead of its theatrical release next month. Also ...
WTIC Hartford on MSN10h
$15 million asbestos verdict delivered against Johnson & Johnson by Connecticut juryA jury in Bridgeport awarded the money to a man who reportedly developed mesothelioma because of asbestos in Johnson & ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback